Related Experiment Video
Updated: May 26, 2026
08:03
Isolation of Salivary Epithelial Cells from Human Salivary Glands for In Vitro Growth as Salispheres or Monolayers
Published on: July 15, 2019
Optimizing Primary Human Salivary Stem/Progenitor Cells for Tissue Engineering Applications
Thaise C Geremias1, Fabio H B da Costa1,2, Nadia G Mohyuddin3
1Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston, Houston, Texas.
Biorxiv : the Preprint Server for Biology
|May 25, 2026
Summary
Researchers developed a new method to grow human salivary stem cells without animal products, crucial for future regenerative therapies for dry mouth. This xeno-free, serum-free process ensures cell purity and viability for clinical applications.
Area of Science:
- Regenerative Medicine
- Stem Cell Biology
- Biotechnology
Background:
- Hyposalivation disorders, or dry mouth, significantly impact quality of life.
- Current treatments are limited, necessitating novel therapeutic approaches.
- Autologous cell therapies offer a promising avenue for salivary gland regeneration.
Purpose of the Study:
- To establish a translationally viable, xeno-free, and serum-free platform for human salivary stem/progenitor cell (hS/PC) isolation and expansion.
- To develop a protocol suitable for regulatory qualification and FDA-approved clinical trials.
- To ensure the purity, safety, and proliferative potential of expanded hS/PCs for autologous regenerative therapy.
Main Methods:
- Human parotid gland tissues were sourced from consented surgical patients.
- Primary hS/PCs were isolated and cultured under animal-component-free conditions.
- CD44+ cells were enriched using magnetic cell sorting, with purity assessed via cytokeratins 5/14, CD133, and fibroblast markers.
Main Results:
- Consistent expansion and epithelial morphology of hS/PCs were achieved in serum-free conditions.
- High CD44 expression (>95%) and negligible contamination by CD133 or fibroblast markers confirmed epithelial purity.
- Senescence-associated beta-galactosidase assays showed only a minor, passage-dependent increase in senescent cells (5-16%).
Conclusions:
- A defined, animal-free culture system effectively supports stable expansion of pure, low-passage hS/PCs.
- The developed protocol is compatible with Good Manufacturing Practice (GMP) standards.
- This platform is suitable for regulatory qualification and advancement towards first-in-human autologous regenerative therapy trials for hyposalivation.
